NCT03773627 (MRIPND) is a clinical trial in Necrosis of Femoral Head, sponsored by RenJi Hospital.

Who is sponsoring NCT03773627?

NCT03773627 is sponsored by RenJi Hospital.

What condition does NCT03773627 study?

NCT03773627 studies Necrosis of Femoral Head, Knee Osteoarthritis, Fracture of Lower Limb.

Is NCT03773627 still recruiting?

NCT03773627 is currently status unknown. Last updated 13 December 2018.

Last reviewed 2018-12-13 · How we verify

NCT03773627: MRIPND

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI Maker of Perioperative Neurocognitive Disorder

Status unknown Last updated 13 December 2018

What this trial tests

trial in Necrosis of Femoral Head in 100 participants. Status unknown.

Timeline

12 December 2018

Primary endpoint
30 December 2019

30 July 2020

Quick facts

Lead sponsor	RenJi Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	12 December 2018
Primary completion	30 December 2019
Estimated completion	30 July 2020
Sites	1 location across China

Conditions studied

Necrosis of Femoral Head — all drugs for Necrosis of Femoral Head →
Knee Osteoarthritis — all drugs for Knee Osteoarthritis →
Fracture of Lower Limb — all drugs for Fracture of Lower Limb →

Sponsor

RenJi Hospital

Who can join

60 and older, any sex, with Necrosis of Femoral Head or Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Periperative neurocognitive disorder(PND) is consistently associated with increased morbidity and mortality, but its mechanisms remain unclear. Moreover, valid biomarkers for the prediction or diagnosis of the development of delayed neurocognitive recovery in aged patients have not been identified so far. The purpose of this study is trying to find the functional MRI marker of PND.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03773627 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 13 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03773627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing